Loading...
•
Sep 27, 2024
Danaher Q3 2024 Earnings Report
Danaher's Q3 2024 performance was marked by revenue growth and market share gains.
Key Takeaways
Danaher reported strong third quarter results with better-than-expected revenue growth, driven by positive momentum in the bioprocessing business and market share gains in molecular testing by Cepheid. Revenues increased by 3.0% year-over-year, and non-GAAP core revenue increased by 0.5%.
Net earnings reached $818 million, with EPS at $1.12 and non-GAAP adjusted EPS at $1.71.
Revenue increased 3.0% year-over-year to $5.8 billion, while non-GAAP core revenue grew by 0.5%.
Operating cash flow was $1.5 billion, and non-GAAP free cash flow amounted to $1.2 billion.
The company anticipates a low-single digit decline in non-GAAP core revenue for Q4 2024 and full year 2024.
Forward Guidance
The Company anticipates that non-GAAP core revenue will decline low-single digits year-over-year for the fourth quarter 2024 and continues to expect that non-GAAP core revenue will be down low-single digits year-over-year for full year 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...